In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

A single injection of a healthy gene allowed blind children to recognize objects, shapes, and even read — offering hope for ...

CompareNetworks is proud to announce the publication of the first issue of Cell & Gene Therapy Review, marking a significant ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

Early results from the company’s single-arm trial saw the therapy able to partially repair the chemical responsible for ...

The vision of one child with AIPL1-associated severe retinal dystrophy improved from light perception to naming his favourite ...

CRISPR is like an editor that can rewrite DNA letter by letter or gene by gene, to remove harmful mutations or add protective ...

Ladies and gentlemen, good morning and welcome to the Taysha Gene Therapies Full Year 2024 Conference Call. At this time all participants are in listen-only mode. A brief question-and-answer session ...

Qure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting ...

Looking forward, greater use of column chromatography technologies in vector manufacturing could facilitate the adoption of ...

"Jim brings a specialized skillset and innovative technology experience at the start of what will be a year of momentum for ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...